Protocol version 9 /Version date 8/June/2021
   1 Investigation of Two Swallowing Therapy Models during R adiation Therapy for 
Head and Neck Cancer   
Document History  Notes  
Version 1       Date: 26 Mar  2019 Initial Approval  
Version 2       Date: 01 Apr 2019  Revision includes:  
• Inclusion/ exclusion criteria (removed repeated 
criteria from the protocol, and pregnant women exclusion)  
• Removed AE/SAE reporting  
• Clarified randomization technique  
• Added demographic survey and INFO 25  
• Modified paper logging form to include date and participation name [CONTACT_298252] 2 additional questions.  
Version 3       Date: 28 May 2019  Revision includes:  
• Formatting changes  
• Updated study calendar and measurement time points to clarify all discrepancies  
• Updated regulatory considerations such as site 
communication and data monitoring to  include management of the various subsites.  
Version 4      Date: 1 JUL 2019  Revision includes:  
• Updating study calendar to clarify procedure collection time window - 4 week +/ - 2 days, 7 
week +/ - 2 days, 19 week +/ - 1 month, 1 year +/ - 
1 month  
• Updated study calendar to allow for baseline 
MBSS to occur up to 2 days after start of 
radiation.  
• Updated section 11.3 to explain how data will be 
managed and stored.  
• Added pre-screening survey (appendix M) to 
allow researchers to ask eligibility questions 
prior to consent.  
Version 5     Date: 10 JAN 2020  Revision includes:  
• Formatting Changes  
• Removed Appendix B (Patient Demographics) 
due to redundancy and clarified data points 
collected in  demographic and medical history 
section of study calendar  
• Removed inconsistencies by [CONTACT_298228] , 
PAS, and INFO 25  in the study calendar  
• Clarified wording of active study duration as 
being seven weeks  
• Removal of wording that had mistakenly been carried over from the previous feasibility study , 
such as the tracking of patient oral intake and 
some app feedback functionalities  
• Clarification that MBSS videos from all sites 
will be stored on Stanford Medicine Box until 
study conclusion  
  
 
Protocol version 9/ Version date 8/June/[ADDRESS_363649] 2020  Revision includes : 
• Added procedure to provide study patients with 
standard scale to measure MIO during video 
visits  
• Addition of list of  participating centers 
(subsites) 
Version 7     Date 9 Dec 2020  Revision Includes:  
• Change in sub -site Principle Investigator at Fox 
Chase Cancer center from Barbara Ebersole to 
Kathleen Donocoff  
Version 8.     Date 29 Mar 2021  Revision Includes;  
• Update to PI [INVESTIGATOR_298208].  
Version 9.    Date 8 June 2021  Revision Includes:  
• Change in Sub -site Principle  investigator at Fox 
Chace Cancer Center from Kathleen Donocoff 
to Liane McCarroll.  
  
 
Protocol version 9/ Version date 8/June/[ADDRESS_363650], CA [ZIP_CODE]  
 
 
[EMAIL_5894] 
 
Co-Investigators  
F. Christopher Holsinger  
Beth Beadle 
[ADDRESS_363651] CA, [ZIP_CODE]  
 
Study Coordinator  
TBD 
  
Version 9 / Version Date: ( 8-Jun-2021) 
 
List of Participating Centers:  
[LOCATION_005] Eye & Ear/ Harvard  
PI: [INVESTIGATOR_298209]: Liane McCarroll  

  
 
Protocol version 9/ Version date 8/June/[ADDRESS_363652] OF ABBREVIATIONS AND DEFINITION OF TERMS  ............................................ 11  
1. OBJECTIVES  ..................................................................................................................... 12  
PRIMARY OBJECTIVE  ................................................................................................................. 12  
1.2. SECONDARY OBJECTIVES  ............................................................................................... 12  
AIM 2: TO EVALUATE THE IMPACT OF THE “HNC VIRTUAL COACH” PROGRAM ON THE PREVALENCE, CHARACTERISTICS, AND SEVERITY OF DYSPHAGIA THREE MONTHS POST- TREATMENT IN PATIENTS UNDERGOING 
RADIATION THERAPY FOR HEAD AND NECK CANCER.  ........................................... [ADDRESS_363653] IN APPENDIX A.  ......... 17  
3.2 INFORMED CONSENT PROCESS  ....................................................................................... 17  
3.3       RANDOMIZATION PROCEDURES  ....................................................................................... 18  
3.4 STUDY TIMELINE  ........................................................................................................... 18  
4. TREATMENT PLAN  ......................................................................................................... 18  
4.1 CRITERIA FOR REMOVAL FROM STUDY  .......................................................................... 22  
4.2 ALTERNATIVES  .............................................................................................................. 22  
5. INVESTIGATIONAL AGENT/DEVICE/PROCEDURE INFORMATION  ............... 22  
5.1  INVESTIGATIONAL AGENT /DEVICE /PROCEDURE  ........................................................... 22  
5.2 AVAILABILITY  ............................................................................................................... 23  
THE MOBILE APPLICATION WILL BE PROVIDED BY [CONTACT_298229] . .......... 23  
5.3 AGENT ORDERING  ......................................................................................................... 23  
6. ADVERSE EVENTS AND REPORTING PROCEDURES  ........................................... 23  
6.1 POTENTIAL ADVERSE EVENTS  ....................................................................................... 23  
  
 
Protocol version 9/ Version date 8/June/2021 
   5 6.2 ADVERSE EVENT REPORTING ......................................................................................... 24  
7. STUDY CALENDAR  ......................................................................................................... 25  
FOOTNOTE: ............................................................................................................................... 25  
1. PROCEDURES TO BE COMPLETED ANY TIME PRIOR TO START OF 
RADIATION TREATMENT. IF SOC PROCEDURES ARE COMPLETED PRIOR TO 
CONSENT, THEY CAN BE INCLUDED, AND DO NOT NEED TO BE REPEATED.  ... 25  
2. PROCEDURES TO BE COMPLETED DURING WEEK 4 OF RADIATION 
TREATMENT (+/ - 2 DAYS).  .................................................................................................... 25  
3. PROCEDURES TO BE COMPLETED DURING FINAL WEEK OF RADIATION 
TREATMENT (+/ - 2 DAYS).  .................................................................................................... 25  
4. PROCEDURES TO BE COMPLETED 3 MONTHS AFTER END OF RADIATION, 
IDEALLY WITHIN (+/ - 2 WEEKS). HOWEVER, IF THE PROCEDURES CANNOT BE 
COMPLETED DURING THAT WINDOW (+/ -) 1 MONTH IS ACCEPTABLE.  .............. 26  
5. PROCEDURES TO BE COMPLETED 1 YEAR AFTER END OF RADIATION (+/ - 1 
MONTH).  ..................................................................................................................................... 26  
6. PRE- STUDY MBSS SHOULD OCCUR PRIOR TO START OF RADIATION 
TREATMENT, BUT CAN ALSO OCCUR WITHIN 2 DAYS AFTER START OF RADIATION.  .............................................................................................................................. 26
 
8. MEASUREMENTS  ............................................................................................................ 27  
8.1  PRIMARY OUTCOME MEASURE  ...................................................................................... 27  
(a) 8. 1.2 Measurement Definition ....................................................................................................................... 27 
(b) 8.1.3 Measurement Methods  ........................................................................................................................... 27 
(c) 8.1.4 Measurement Time Points .......................................................................................................................... 27 
8.2A  SECONDARY OUTCOME MEASURES (THESE MEASURES , IN COMBINATION , PROVIDE A 
COMPREHENSIVE EVALUATION OF SWALLOWING PHYSIOLOGY , ITS FUNCTIONAL IMPACT , AND 
PATIENT PERCEPTION .) ............................................................................................................... 27  
(d) 8.2a.2 Measurement Definition  ..................................................................................................................... 27 
(e) 8.2a.3 Measurement Methods  ........................................................................................................................ 28 
(f) 8.2a.4 Measurement Time Points ....................................................................................................................... 28 
8.2B  SECONDARY OUTCOME MEASURE  .................................................................................. 28  
(g) 8.2b.2 Measurement Definition  ..................................................................................................................... 28 
(h) 8.2b.3 Measurement Methods  ........................................................................................................................ 28 
(i) 8.2b.4 Measurement Time Points  ....................................................................................................................... 28 
8.2C  SECONDARY OUTCOME MEASURE  .................................................................................. 28  
(j) 8.2c.2 Measurement Definition  ........................................................................................................................... 28 
(k)
 8.2c.3 Measurement Methods  ......................................................................................................................... 28 
(l) 8.2c.4 Measurement Time Points ....................................................................................................................... 29 
8.2D  SECONDARY OUTCOME MEASURE  .................................................................................. 29  
(m) 8.2d.2 Measurement Definition  ..................................................................................................................... 29 
(n) 8.2d.3 Measurement Methods  ........................................................................................................................ 29 
8.2D.4 MEASUREMENT TIME POINTS  ......................................................................................... 29  
8.2E  SECONDARY OUTCOME MEASURE  .................................................................................. 29  
(o) 8.2e.2 Measurement Definition ...................................................................................................................... 29 
(p) 8.2e.3 Measurement Methods  ......................................................................................................................... 29 
  
 
Protocol version 9/ Version date 8/June/2021 
   6 (q) 8.2e.4 Measurement Time Points .................................................................................................................. 29 
8.2F  SECONDARY OUTCOME MEASURE  .................................................................................. 29  
(r) 8.2f.2 Measurement Definition ............................................................................................................................ 30 
(s) 8.2f.3 Measurement Methods  ............................................................................................................................... 30 
(t) 8.2f.4 Measurement Time Points ........................................................................................................................ 30 
8.2G  SECONDARY OUTCOME MEASURE  .................................................................................. 30  
(u) 8.2g.2 Measurement Definition  ..................................................................................................................... 30 
(v) 8.2g.3 Measurement Methods  ........................................................................................................................ 30 
(w) 8.2g.4 Measurement Time Points  ................................................................................................................. 30 
9. MULTISITE REGULATORY CONSIDERATIONS  ..................................................... 30  
11.1  MONITORING PLAN  ........................................................................................................ 30  
11.2   PROTOCOL REVIEW AND AMENDMENTS  ............................................................................ 31  
11.3   DATA MANAGEMENT  ......................................................................................................... 31  
11.4  STUDY DOCUMENTATION  .............................................................................................. 32  
11.5  SITE COMMUNICATION  .................................................................................................. 33  
10. STATISTICAL CONSIDERATIONS  .......................................................................... 33  
10.1  STATISTICAL DESIGN  ..................................................................................................... 33  
(x) Randomization  ...................................................................................................................................................... 33 
RANDOMIZATION WILL BE CARRIED OUT USING PRE- PRINTED LISTS WITH 
BLOCK SIZE OF 4 VIAONCORE. .......................................................................................... 33  
10.4  PRIMARY ANALYSIS  ....................................................................................................... 33  
(y) Analysis Population ............................................................................................................................................. 33 
(z) Analysis Plan  .......................................................................................................................................................... 34 
12.5  SECONDARY ANALYSIS  .................................................................................................. 34  
(aa)  12.5.1 Analysis Population  ............................................................................................................................... 34 
(bb)  12.5.2  Analysis Plan  ........................................................................................................................................... 34 
12.6   SAMPLE SIZE .................................................................................................................. 34  
(cc) 12.6.1 Accrual estimates  ................................................................................................................................... 34 
(dd)  12.6.2 Sample size justification  ..................................................................................................................... 34 
(ee)  12.6.[ADDRESS_363654] size justification ......................................................................................................................... 34 
13. REFERENCES  ................................................................................................................ 35  
APPENDICES  ............................................................................................................................. 43  
APPENDIX  A: PARTICIPANT ELIGIBILITY CHECKLIST  ............................................................. 43  
SUPPORTING DOCUMENTATION*  ...................................................................................... 43  
APPENDIX B: PATIENT DEMOGRAPHICS  ............................... ERROR ! BOOKMARK NOT DEFINED . 
APPENDIX C: PATIENT COMFORT WITH TECHNOLOGY  ............................................................... 45  
1. DO YOU OWN EITHER AN ANDROID OR APPLE-IOS BASED SMARTPHONE OR TABLET ? .. [ADDRESS_363655] ACCESS TO AN INTERNET CONNECTION OR A SUFFICIENT MONTHLY DATA 
PLAN (~200MB/ MONTH ) OR GREATER ? ................................................................................... 45  
APPENDIX D: PAPER LOGGING FORM  ......................................................................................... 46  
PARTICIPANT NAME: ______________________________________ ..................................... 46  
APPENDIX E: MD  ANDERSON DYSPHAGIA INVENTORY  ............................................................. 47  
APPENDIX F: FUNCTIONAL ORAL INTAKE SCALE (FOIS)  .......................................................... 49  
APPENDIX G: PERFORMANCE STATUS SCALE – HEAD AND NECK .............................................. 50  
APPENDIX H: PENETRATION ASPI[INVESTIGATOR_298210]  ....................................................................... 51  
  
 
Protocol version 9/ Version date 8/June/2021 
   7 APPENDIX I: MODIFIED BARIUM SWALLOW IMPAIRMENT PROFILE (MBS -IMP) ........................ 52  
APPENDIX J: DYNAMIC IMAGING GRADE OF  SWALLOWING TOXICITY  ...................................... 53  
APPENDIX K: INFO  25 SURVEY  ................................................................................................. 54  
....................................................................................................................................................... 54  
APPENDIX L: DEMOGRAPHIC SURVEY  ....................................................................................... 56  
....................................................................................................................................................... 56  
APPENDIX M: PRE-SCREENING QUESTIONNAIRE  ........................................................................ 57  
  
 
Protocol version 9/ Version date 8/June/[ADDRESS_363656] OR 
PROCEDURE  Vibrent mobile application  
PRIMARY OBJECTIVE(S)  To evaluate the impact of the “ HNC 
Virtual Coach ” mobile application on 
patient adherence to a prescribed 
swallowing therapy protocol.  
SECONDARY OBJECTIVE(S)  To evaluate the impact of the “ HNC 
Virtual Coach ” program on the 
prevalence, characteristics, and severity of dysphagia three months post-treatment in patients undergoing 
radiation therapy for head and neck 
cancer.  
TREATMENT SUMMARY  Participants in the experimental arm 
(Group A) will receive a comprehensive 
swallowing rehabilitation app (“ HNC 
Virtual Coach ”). The paper group 
(Group B) will be given paper exercise 
logs to fill out.  
SAMPLE SIZE  176 
STATISTICAL CONSIDERATIONS  88 patients will be enrolled in each arm.  
This number will provide 80% power to 
detect a 15 percentage point difference between groups.  This calculation is made assuming 33% adherence in arm B and a standard deviation of 32 based on prior studies.  This sample size includes the addition of 20% to account for anticipated drop out.  
 
The proposed research is a RCT with a primary aim of determining if a mobile application may enhance adherence to swallowing therapy in patients undergoing radiation for head and neck 
cancer thus improving swallowing 
  
 
Protocol version 9/ Version date 8/June/2021 
   9 outcomes.  Analysis of the primary 
endpoint (adherence) will be carried out 
using logistic regression, comparing arms A and B.  A secondary endpoint will be the average percent adherence per week.  Analysis of the secondary adherence endpoint will be carried out using a linear mixed effect model with weekly adherence as a dependent variable, a patient -specific random 
intercept, treatment arm as the primary predictor, and week as a fixed (categorical) effect. We will also explore the impact of the mobile app on 
a variety of swallowing outcomes including diet level, patient perception, and physiological measures.  Analysis of these endpoints will be carried out using logistic regression comparing 
arms A and B.  
Protocol version 9 /Version date 8/June/2021 10SCHEMA
Potential 
participants
≥ [ADDRESS_363657] either an 
Android or Apple iOS-
based smartphone or 
tablet
Access 
to a 
sufficien
t 
monthly 
data 
plan 
Candidates 
enrolled and 
randomized 
(n=176)
Arm A 
(n=88)
7 week treatment 
Primary outcome 
measured 
(adherence)
2-[ADDRESS_363658] 
treatment 
secondary outcomes 
measured
(MBS)
1 year follow up
years of 
Arm B 
(n=88)
No prior history 
7 week treatment 
Primary outcome 
measured 
(adherence)
2-[ADDRESS_363659] treatment 
Secondary outcomes 
measured
(MBS)
Protocol version 9 /Version date 8/June/[ADDRESS_363660]  
SRC  Scientific review committee  
TORS  Transoral robotic surgery  
WHO  World Health Organization  
UNK  Unknown  
WBC  White blood cell  
WHO  World Health Organization  
 
 
Protocol version 9 /Version date 8 / June/[ADDRESS_363661] of the “ HNC Virtual 
Coach ” mobile application on adherence to prophylactic swallowing therapy during head and 
neck radiation . Prior studies have demonstrated the value of mobile health technologies in 
improving patient adherence in a variety of settings, including exercise programs (Guarino et al., 
2016; Hui et al., 2016, Carter et al 2013). Preliminary feasibility data collected by [CONTACT_298230] “ HNC Virtual Coach ” program could be easily integrated into standard care 
and lead to high levels of patient engagement in their swallowing exe rcise program. (Starmer 
2017)  Our central hypothesis is that patients randomized to use the “ HNC Virtual Coach ” 
application will demonstrate better adherence to swallowing exercises, translating to better functional swallowing outcomes, than patients receiving usual care. We propose to achieve our objective by [CONTACT_172093]. 
 
Aim 1: To evaluate the impact of the “HNC Virtual Coach” mobile application on patient adherence to a prescribed swallowing therapy protocol.  
 
1.2. Secondary Objectives   
 
Aim 2: To evaluate the impact of the “HNC Virtual Coach ” program on the prevalence, 
characteristics, and severity of dysphagia three months post -treatment in patients 
undergoing radiation therapy for head and neck cancer . 
 
2. BACKGROUND  
 2.1 Study Disease  
 
Head and neck cancer (HNC) is the [ADDRESS_363662] common type of cancer in the world and has 
recently seen a dramatic rise in the [LOCATION_002] secondary to oropharyngeal tumors related to 
the human papi[INVESTIGATOR_28597] (HPV) (Chaturvedi et al., 2008).  Patients with HPV -associated HNC 
tend to be younger and healthier at diagnosis than patients with “traditional” head and neck cancer risk factors related to alcohol and tobacco consumption (Gillison et al., 2008).  Hence, the majority of patients who will develop HNC in 2018 (and beyond) will have fewer competing morbidities than traditional patients and are expected to have long lifespans in which to develop potential toxicity of treatment.  In addition, patients with HPV -associated HNC have markedly 
better oncologic outcomes, when matched with other variables, compared to traditional HNC (Fakhry et al., 2008).  Overall, the need to providing effective cancer therapy, with minimal side effects, is especially important in this cohort of modern patients with HNC.   For patients with newly diagnosed HNC, treatment may include surgery, radiation, and/or chemotherapy, often delivered in combination.  The majority of patients receive radiation therapy at some point in their treatment, either as definitive treatment or in  the post- operative 
 
Protocol version 9 /Version date 8 / June/[ADDRESS_363663] set of potential acute and long -term side 
effects, and the combination of therapi[INVESTIGATOR_298211]- term toxicity (Rosenthal 
2014; Gane et al 2017).  Modern advancements in surgery (namely, transoral robotic surgery, 
TORS), radiation therapy (namely, intensity -modulated radiation therapy, IMRT), and 
chemotherapy (namely, the use of novel systemic agents) all have shared minimizing toxicity as a primary goal.  However, treatment still has significant impact on quality of life as noted by [CONTACT_28460] (Ringash 2015; Jones 2017; Achim 2017).    Dysphagia is one of the most common sequelae of HNC and its treatment. The increased use of definitive radiation -based treatment (without surgery) to allow for organ preservation has led to a 
growing awareness of the potential f or dysphagia from this approach. This is likely related to 
radiation fibrosis and changes in innervation of the muscles of swallowing (King et al., 2016).  The use of radiation and chemotherapy has been beneficial in sparing the consequences of surgery and removal of tissues involved in swallowing; however, the preservation of an organ when treating HNC does not necessarily equate to the preservation of function.  A substantial body of evidence suggests that patients receiving non- surgical treatment for HNC are at risk for 
both acute toxicities and long- term alteration of swallow function (Starmer et al., 2014; 
Hutcheson et al., 2012; Eisbruch et al., 2002). Such alterations may contribute to long- term 
decrements in health status and quality of life
 (Daugaard et al., 2017; Silveira et al., 2015; 
Ringash 2015). It has become increasingly apparent that prevention of dysphagia through active 
participation in prophylactic swallowing therapy with speech-language pathologists (SLP) can positively affect these outcomes (Carroll 2008; Kotz 2012; Carnaby-Mann 2012).  The data supporting the use of prophylactic swallowing exercises includes multiple outcome measurements.  Carroll and colleagues
 (2008) demonstrated that individuals performing 
swallowing exercises prior to and during chemoradiation demonstrated more normal tongue base apposition to the posterior pharyngeal wall during swallowing as well as more normal epi[INVESTIGATOR_298212] a matched group of patients who started exercises 
after completion of radiation suggesting the beneficial impact of preventative exercises on physiology. Further, Kotz and colleagues (2012) demonstrated more favorable diet levels 3-6 months following completion of treatment in patients completing preventative exercises.  Carnaby-Mann (2012) used post-t reatment muscle size/composition as measured by [CONTACT_298231]. In the active treatment arm in which patients performed swallowing exercises twice daily over the du ration of treatment, there was less structural change in the genioglossus, hyoglossus, 
and myohyloid muscles than in the other two treatment groups.  A composite measure was designed to designate a favorable swallowing-related outcome, and included weight loss <10%, maintenance of oral diet, and a change of <10 points on the Mann Assessment of Swallowing Ability (MASA).  In the active treatment arm, 86% achieved this desirable outcome, while only 47% in the other groups achieved this.  There was a 36% absolute risk reduction for loss of swallowing ability when participating in preventative exercise. These results serve as strong evidence that patients receiving non -operative HNC treatment should be engaged in swallowing 
therapy prior to the start of radiation.    Swallowing therapy may include a number of interventions, including compensatory strategies that work to impact bolus flow, as well as exercises which aim to influence swallowing 
 
Protocol version 9 /Version date 8 / June/2021
    14 physiology.  Swallowing exercises are typi[INVESTIGATOR_298213] a SLP based on physiologic findings 
during an instrumental swallowing evaluation; modified barium swallow (MBS) or flexible fiberoptic endoscopic evaluation of swallowing (FEES).  Exercises are designed to improve the safety and/or efficiency of the swallow and may target structures such as the tongue, pharyngeal constrictors, and suprahyoid musculature.  Exercises such as the effortful swallow, Mendelsohn maneuver, and the Masako technique have been shown to be effective in improving the strength of the muscles of deglutition (Lazarus 2002, Hoffman 2012, Fujiu 1996). Additionally, in the case of patients undergoing radiation therapy, range of motion stretches may target structures within the field of radiation, such as the tongue and the masseter muscles (Logemann 1997).  Dysphagia exercises are typi[INVESTIGATOR_298214].  
 Patient adherence to treatment recommendations requires that patients be active participants in their care.  Prior studies of adherence in the exercise literature show that adherence rates tend to be poorer in patients engaging in home exercise programs than those receiving clinical therapy (Forkan 2006, Hardage 2007).  In addition, for patients with HNC, oncologic treatment itself may be cumbersome (including multiple daily appointments) and painful, and patient understanding of treatment recommendations can be lacking.  Increasing patient comprehension of the importance of swallowing intervention is critical for improving adherence.  Multiple recent reports have demonstrated that adherence to swallowing therapy recommendations is poor in patients with HNC (Table 1).  
 Table 1: Studies reporting adherence rates to swallowing therapy  
 
Reference  Population  Adherence rate  
Wall, 2017  Head and neck cancer 
radiation  27% 
Cnossen, 2017  Head and neck cancer 
radiation  38-70% 
Mortensen, 2015  Head and neck cancer 
radiation  33-53% 
Shinn, 2013  Head and neck cancer 
radiation  13-45% 
Kotz, 2012  Head and neck cancer 
radiation  31% 
 These studies repeatedly demonstrate that ~2/3 of patients do not follow through with recommended swallowing therapy protocols, demonstrating the critical need for head and neck care teams need to determine strategies that facilitate patient adherence.  Pr ior work by [CONTACT_298232] (Starmer et al., 2011).  In addition, through collaborations within the 
multidisciplinary team, our group is assessing strategies to minimize treatment toxicity, such as pain, using gabapentin to block nerve related pain and optimize functionality (Yang et al., 2016; Starmer et al., 2014).  With this proposal, we further advance this initiative by [CONTACT_2329] a mobile health application specifically designed to address these issues to assist in difficulty performing 
 
Protocol version 9 /Version date 8 / June/2021
    15 the exercises, remembering the exercises, and understanding the rationale for the exercises.  
The World Health Organization (WHO) has classified factors that may impact patient adherence 
into five distinct groupi[INVESTIGATOR_14839]: patient- related, socio -economic, therapy-related, condition- related, 
and health care system related factors (Sabate 2003).  While man y of these factors cannot be 
regulated by [CONTACT_298233], others such as therapy -related and health care system factors 
may be manipulated to optimize adherence.  Mobile health technology has been proposed as a tool to influence such barriers to adhe rence.  There are multiple studies that have shown the 
positive impact of mobile health technology, including use in methadone clinics and asthma management clinics (Guarino et al., 2016; Hui et al., 2016).  With regard to exercise programs, use of mobile applications has been associated with higher levels of exercise in contrast to paper logging programs.  Carter et al. (2013) reported nearly double the rates of exer cise program 
retention at 6 months (93% versus 53%) and nearly triple the exercise logged (92 days versus 29 days) when a mobile health application was integrated into a weight loss program, leading to a greater degree of weight loss and BMI change.  
 
2.2 Study Agent/Device/Procedure The “ HNC Virtual Coach ” program has been developed in 
conjunction with Vibrent Health ( www.vibrenthealth.com ), a cloud- based precision health 
platform for individual and population health. The Vibrent team has partnered with stakeholders 
across the healthcare ecosystem to advance disease prevention and treatment based on real -world 
evidence and scientific rigor. Vibrent has experience with leading edge technologies for both commercial contracts and academic grant projects including adaptive algorithms, wireless 
wearables and medical devices, passive sensing, predictive modeling, machine learning, adaptive tailored messaging, dynamic automated care planning, big health data system integration, genomics, and more.  Vibrent was recently chosen by [CONTACT_7681] (NIH) to provide the technology backbone for its historic Precision Medicine Initiative 
(www.joinallofus.org), engaging millions of Americans over the next ten years. This 
groundbreaking effort aims to engage more than one million participants to understand how genomics, lifestyle, behavioral, and environmental factors impact an individual’s health.  For the purpose of the current investigation, Vibrent Health will partner with head and neck cancer teams at a num ber of National Cancer Institute designated Comprehensive Cancer Centers to 
optimize and evaluate a precision health platform to facilitate patient adherence to swallowing exercises and optimize functional swallowing outcomes.  
 
2.3 Rationale 
This protocol seeks to address the issue of low adherence to swallowing exercises by [CONTACT_67940] a customizable mobile application (“ HNC Virtual Coach ”) as an adjunct to routine 
clinic visits and instruction from SLPs.  Prior studies which have demonstrated improved adherence in the setting of weight loss and non- cancer medical management suggest that this 
approach is feasible; our hypothesis is that a mobile health application will improve adherence to 
swallowing exercises.  However, performance of the ex ercises is not the only endpoint.  Multiple 
studies have shown that improved exercise adherence results in notable benefits with regard to swallowing function.  Our second hypothesis is that increased adherence to swallowing exercises will then lead to pre servation of functional swallowing physiology and subsequently to increased 
swallowing safety, efficiency, and patient perceived quality of life. The “ HNC Virtual Coach ” application, tailored to patients with HNC, will monitor patient 
progress while also providing a direct line of communication to health care providers should any 
 
Protocol version 9 /Version date 8 / June/2021
    16 questions or concerns arise concerning their treatment. The mobile application will also feature 
instructional videos that describe the swallowing exercises in detail, providing patients with another resource to help improve their overall rehabilitation ex perience. Finally, home practice 
reminders and prompts will be used to help patients integrate the exercises into their daily routine.  We seek to demonstrate that use of the “ HNC Virtual Coach ” program will be 
associated with greater adherence to home exercise protocols as measured by [CONTACT_298234].  This hypothesis is based on our preliminary feasibility data and patient feedback regarding the value of the application to their treatment (Starmer et al 2017).  Specific feedback from participan ts in the feasibility trial included:  
 
Feasibility trial participant feedback  
“ I felt like my therapi[INVESTIGATOR_298215].  All of my family and 
friends felt like they knew her.”  
“The app was good because it made me feel like if I didn’t do the exercises, the teacher 
would yell at me.”  
“I knew when to do my exercises.  Keepi[INVESTIGATOR_298216].”  
“It is easy, you don’t have to be computer literate to use it.”  
 A feasibility study investigating the approach of using a mobile technology application (in general) and the “ Swallow for Life ” swallowing therapy application (specifically) in patients 
with HNC has recently been completed through a collaboration between Stanford University and Johns Hopkins University, under the guidance of PI [INVESTIGATOR_298217].  A total of [ADDRESS_363664] from the 
patients.  The majority of patients were diagnosed with oropharyngeal squamous cell carcinoma 
(83%), and most received chemoradiation as their primary treatment (75%).  Overall, there were 
[ADDRESS_363665] two exercise sessions per day were entered by 25% of participants and at least one session per day was logged by 53% of participants.  While a 53% partial adherence rate may seem meager, prior studies demonstrated adherence rates closer to 30 -40% (Table 1).  Thus, 
while not directly comparable, there is reason to believe that use of this mobile application may in fact be an effective tool to enha nce adherence.  Only 20% of participants did not meaningfully 
engage with the application (i.e. less than 10 logs total over study duration).  The average number of exercise sessions logged was 44; however if those who did not engage with the application w ere excluded from analysis, this number rose to 60 sessions logged.  On average, 
participants logged their weight 27 times and their pain 65 times over the course of the study.  Intra -app surveys regarding failure to log exercises were completed 71 times b y 23 unique 
patients.  Entries revealed the majority of patients had completed the exercises but forgot to log them (70%) suggesting that actual adherence rates may have been underestimated in this series.  Other reasons for failure to log included; time constraints (13%), fatigue (6%), pain (6%), app/internet issues (4%), and lack of understanding of the exercises (1%).  Exit interviews of patients revealed overall satisfaction with the app.  Features cited as most beneficial included: use of videos to reinforce exercise technique, reminders to keep on track with exercises, and a feeling of increased accountability.  Based on the outcomes of this study and the feedback received from patients, our study team has worked extensively with the Vibrent program development team to optimize the mobile
 application for the purpose of this clinical trial.  
 
Protocol version 9 /Version date 8 / June/2021
    17 Revisions include: simplification of the logging system, patient customization of reminders, 
reducing unnecessary notifications, and improving the user interface.  While this feasibility trial was not designed to determine relative adherence between patien ts using the app and those 
receiving standard care, preliminary data suggest this intervention may be an effective adjunct to standard treatment, thus prompting the need for further investigation.  
 
2.[ADDRESS_363666] Clinical Trials Directory compliance  
 State the primary purpose for the protocol from the following choices:  
Supportive Care: protocol designed to evaluate one or more interventions where the primary intent is to maximize comfort, minimize side effects or mitigate against a decline in the subject’s health or function.  In general, supportive care interventions ar e not intended to cure a disease.  
  State the interventional model from these choices:  Parallel: one of two groups in parallel for duration of study.   State the number of intervention arms.  2  State whether the study will be masked (at least one party is unaware of the treatment)  
Single Blind: one party is unaware of the intervention assignment,   State whether the study is randomized.  Participants will be randomized to treatment arms  
 State type of primary outcome or outcome that the protocol is designed to evaluate:  Efficacy  
 
2.[ADDRESS_363667] in Appendix A.  
 
3.1 Inclusion/ Exclusion Criteria  We have decided not to duplicate the inclusion/exclusion 
criteria here, please refer to Appendix A.  
 
3.[ADDRESS_363668] receive a copy of the signed and dated consent document.  The original 
 
Protocol version 9 /Version date 8 / June/[ADDRESS_363669] or research file.  
 
3.3       Randomization Procedures  
Following enrollment, randomization will be carried out using pre -printed lists with block size of 
4 through OnCore .  Clinical research coordinators will complete the randomization process after 
consent completed.   
3.4 Study Timeline  
Primary Completion:  
The study will reach primary completion 24 months from the time the study opens to accrual. 
 Study Completion:  
The study will reach study completion 36 months from the time the study opens to accrual. 
 
4. TREATMENT PLAN  
We propose a randomized control trial with two arms; the experimental “ HNC Virtual Coach ”
 
app group (Group A, n=88), and a paper logging control group (Group B, n=88). In clinical 
practice, many patients would not even complete paper log forms, therefore the act of logging alone may inflate adherence values.  However, the ability to measure adh erence across study 
groups required some level of logging to minimize the potential for recall bias.  As a result, inclusion of the paper logging groups appeared to be the best compromise for comparing our experimental intervention with usual care. We hypothesize that those participants in Group A will complete a higher percentage of prescribed exercises than those in group B.  Additionally, we hypothesize that those individuals in Group A will have more favorable swallowing outcomes as defined below.    Participants in the experimental arm (Group A) will receive a comprehensive swallowing 
rehabilitation app (“ HNC Virtual Coach ”). The paper group (Group B) will be given paper 
exercise logs to fill out.  All patients will consult with a SLP prior to the initiation of radiation therapy.  At that time, baseline evaluations of swallowing function (outlined below) will be performed. All participants will be educated regarding potential radiation -related side effects and 
trained in the same series of swallowing exercises by [CONTACT_127428].  In order to ensure fidelity of the target interventions, each SLP involved in this study will complete training with the site PI [INVESTIGATOR_298218].  SLPs will ensure that the patient is able to return demonstrate each exercise during their visit. 
  Patients with elevated risk for developi[INVESTIGATOR_298219]- radiation will be the target of 
this intervention.  This includes individuals with primary head and neck tumors in the oral cavity, oropharynx, nasopharynx, larynx, and hypopharynx requiring bilateral neck radiation.  Patients with recurrent disease will be excluded from participation.  Detailed inclusion and exclusion criteria can be found in Appendix A.  Patients will be screened for eligibility, consented, enrolled, and randomized prior to the initiation of radiation therapy. Eligibility screening will be conducted through weekly screening of radiation oncology clinics, new patient 
referrals and tumor board patient lists.  Those individuals identified as candidates for the study 
will be contact[CONTACT_298235].  Interested participants will 
 
Protocol version 9 /Version date 8 / June/2021
    19 be consented using an IRB approved consent form. Informed consent will explain to participants 
that they will receive an intervention to support their swallowing therapy during radiation.  Following enrollment, randomization will be carried out using pre -printed lists with random 
block size. Subjects will meet with a member of the research team for a baseline visit that will review details on how to download and use the application or how to complete paper exercise logs.  Written instructions regarding the app will be provided for patient reference at home. Participants will then be instructed to use the “ HNC Virtual Coach ” app in order to log daily 
exercises over the course of their treatment.  All study subjects will proceed to routine clinical care, consisting of standard fractionated radiotherapy with or without concurrent chemotherapy (based on standard clinical indications).  Participants in the experimental arm will be asked to use the “HNC Virtual Coach ” program as an adjunct to standard care during treatment. The 
active study duration for each participant will begin on the first day of radiation. All participants will receive standard care with the SLP with planned clinical visits scheduled at the begin ning of 
radiation, mid -way through radiation, and at the conclusion of radiation. 
 We have developed a demographic information instrument to allow us to properly describe our cohort and to examine possible effects of these factors on adherence and functional outcome measures. (Appendix L ) Variables of interest include age, sex, ethnicity , disease stage, disease 
site, HPV status, education level, marital status, distance from home to treatment center, and insurance status.  Additionally, participants will be asked to rate their comfort level with smartphone technology using a visual analog ue scale (Appendix C ).  These will be completed at 
the time of study enrollment, prior to randomization.  
 Participants will be asked to complete and log their swallow exercises using either the Vibrent application or paper forms throughout the duration of radiation therapy. The Vibrent application 
will time stamp the date and time of data entry for secondary analysis to determine whether 
logging occurs on a daily basis or in batch. Paper logs will be collected by [CONTACT_298236] a central Redcap database. Each patient’s program will ask the patient to complete 3 sets of ten repetitions of four different exercises, twice each day: Jaw stretches, Effortful Swallow, Mendelsohn Maneuver, and the Masako Maneuver. These maneuvers have all been well described and validated in the literature for patients undergoing treatment for head and neck cancer (Pauloski 2008).   Participants in the experimental arm (Group A) will receive a notification reminder to complete target exercises as well as a link to a video workout twice each day through the mobile application. Additional educational videos will also be made available through the “ HNC Virtual 
Coach ” program to support the patient with treatment -related toxicities that may impact exercise 
adherence during radiation (such as pain, fatigue, and xerostomia). All of these exercises and additional information are within the no rmal standard of care and are simply facilitated outside 
of the clinical setting by [CONTACT_941] “ HNC Virtual Coach ” program.  When two sequential exercise 
sessions in a row are not completed, the application will push a survey to the participant to ascertain the reason why the sessions were not completed. Available options will include: 1) Didn’t have time, 2) Pain, 3) Not feeling well/no energy, 4) Don’t know how to do them, 5) Don’t think they are necessary, 6) Issues with technology, and 7) Other.  Based on part icipant 
responses, the study team will have the option to push information to the participant to address cited issues. During the baseline visit, the patients will be instructed that this mode of 
 
Protocol version 9 /Version date 8 / June/[ADDRESS_363670] modes of communication with their 
provider, or obviate the need for scheduled follow-up visits.  The communication portal rather serves as a real -time feedback component on the patients “out of clini c” course of treatment.  
Instructions will be given regarding any emergencies, with directions to not communicate via the system and to call [ADDRESS_363671] data regarding pain on a scale of 1 -10 daily, where 1=no pain and 10=severe pain.  
This will allow investigators to monitor pain as a variable that may impact adherence.  Additionally, in order to evaluate the relative role of oral intake during treatment, participants will be as ked to rate their oral intake for nutrition/hydration as “all”, “some”, or “none” on a 
daily basis.  Participants in the paper control group (Group B) will be asked to log exercises on provided logging sheets (Appendix D).  Both groups will be asked to rate their pain on a scale of 1-[ADDRESS_363672] been reported in the literature; however these have been shown to have limited reliability and validity (McLean 2017).  In the absence of validated, reliable measures of adherence, patient logging remains the mainstay for measuring adherence in the majority of the exercise literature. The reliance on patient logging across treatment arms will minimize the risk 
for reporting bias in this study.  
 Aim 1: To evaluate the impact of the “HNC Virtual Coach” mobile application on patient adherence to a prescribed swallowing therapy protocol.  
 
Primary outcome variable : Overall adherence to prescribed exercise protocol measured as 
percentage of prescribed exercises completed over a seven -week period. (i.e. if participants are 
asked to complete 6 sets of 10 reps of each exercise daily for 7 weeks, maximum potential would 
be 420 sets).  Aim 2: To evaluate the impact of the “HNC Virtual Coach ” program on the prevalence, 
characteristics, and severity of dysphagia in patients undergoing radiation therapy for head and neck cancer.  
 Secondary outcome variables : 
Patient reported:  
MD Anderson Dysphagia Inventory (MDADI) (Appendix E)  Clinician reported:  
Functional Oral  Intake Score (FOIS) (Appendix F ) 
Performance Status Scale – He ad and neck (PSS HN) (Appendix G) 
 Functional measures obtained during videofluoroscopic swallowing studies (VFSS): Penetration As pi[INVESTIGATOR_127353] (PAS) (Appendix H) 
Individual item and composite scores of the Modified Barium Swallow Impairment Profile (MBS -ImP)  (Appendix I) 
 
Protocol version 9 /Version date 8 / June/2021
    21 Dynamic Imaging Grade of Swallowing Toxicity (DIG EST) severity scores (Appendix J) 
Maximal interincisor distance  
 
 See study calendar for when these outcome measures will be collected  
  Modified barium swallow procedure:  All MBS studies will follow a standard protocol.  
Additional boluses or strategies may be employed by [CONTACT_298237].  Examinations will be conducted using a minimum of 30 frames per second and recorded for review purposes. Studies will be saved in AVI or MPEG format. Patients will be evaluated while seated in lateral and frontal views with views to include the soft palate superiorly, the cricopharyngeus in feriorly, the lips anteriorly, and the cervical 
spi[INVESTIGATOR_248727]. A penny will be taped to the participant’s chin during the evaluation to provide calibration for measurements performed following the MBS. Varibar contrast will be us ed in 
trials as outlined below:  
Lateral view: 5cc Varibar thin liquid X2 
    10cc Varibar thin liquid X1  
    20cc Varibar thin liquid X1  
    Ungraded cup sip Varibar thin liquid X2     5cc Varibar pudding X2     ½ graham cracker coated with 3ml Varibar pudding X1  Frontal view:  20cc Varibar thin liquid bolus X1 
 MBS videos from all sites may be stored in Stanford Medicine Box until the study’s completion. The m odified barium swallow videos will then be reviewed by a Stanford  MBS -ImP trained SLP 
blinded to treatment group .  
 The MD Anderson Dysphagia Inventory (MDADI) was selected to capture and quantify the patient perception of swallowing dysfunction.  It is a 20- item patient reported survey that 
measures the impact of dysphagia on patients with HNC.  Each item is rated on a  scale of [ADDRESS_363673] of dysphagia on head and neck cancer patients (Chen 2001).     In order to describe patient diet levels, the Functional Oral Intake Scale was selected.  
The FOIS is a [ADDRESS_363674] very good inter- rater 
reliability and validity (Crary 2005).  It has been used extensively in studies of dysphagia in the head and neck cancer population.    The Performance Status Scale – Head and Neck (PSS-HN) was chosen to provide 
additional detail regarding diet and eating restrictions. This measure has been validated and shown to have good correlation with other measures of function in this population (List 1990).   In order to measure physiologic swallow function during MBS studies, three assessment 
 
Protocol version 9 /Version date 8 / June/[ADDRESS_363675] favorable intra - and inter- judge 
reliability (Rosenbek 1996).  
  The Modified Barium Swallow Impairment Profile is a tool designed to quantify degree 
of impairment on [ADDRESS_363676] greater dysfunction.  This tool correlates significantly with other measures of swallowing including penetration aspi[INVESTIGATOR_298220], diet scores, and quality of life (Martin -Harris 2008). 
  The Dynamic Imaging Grade of Swallowing Toxicity was established to rate the safety and efficiency of the pharyngeal swallow during modified barium swallow studies using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE) framework.  The scale has been shown to correlate with the MBSImp composite score, MDADI, and oral intake levels (Hutcheson 2017).   These measures, in combination, provide a comprehensive evaluation of swallowing physiology, its functional impact, and patient perception. 
4.[ADDRESS_363677] clinical care.  
 
5. INVESTIGATIONAL AGENT/DEVICE/PROCEDURE INFORMATION  
5.1  Investigational Agent/Device/Procedure   
The “ HNC Virtual Coach ” program has been developed in conjunction with Vibrent Health 
(www.vibrenthealth.com ), a cloud-based precision health platform for individual and population 
health. The Vibrent team has partnered with stakeholders across the healthcare ecosystem to 
advance disease prevention and treatment based on real -world evidence and scientific rigor. 
Vibrent has experience with leading edge technologies for both commercial contracts and academic grant projects including adaptive algorithms, wireless wearables and medical devices, passive sensing, predictive modeling, machine learning, adaptive tailore d messaging, dynamic 
automated care planning, big health data system integration, genomics, and more.  Vibrent was recently chosen by [CONTACT_7681] (NIH) to  provide the technology backbone 
for its historic Precision Medicine Initiative (www.joinallofus.org), engaging millions of Americans over the next ten years. This groundbreaking effort aims to engage more than one million participants to understand how genomics, lifestyle, behavioral, and environmental factors 
impact an individual’s health.  For the purpose of the current investigation, Vibrent Health will 
partner with head and neck cancer teams at a number of National Cancer Institute designated 
 
Protocol version 9 /Version date 8 / June/[ADDRESS_363678] Clinical Trials Directory compliance  
  Intervention Description   
Participants in the experimental arm (Group A) will receive a notification reminder to complete 
target exercises as well as a link to a video workout twice each day through the mobile application. Additional educational videos will also be made available through the “ HNC Virtual 
Coach ” program to support the patient with treatment -related toxicities that may impact exercise 
adherence during radiation (such as pain, fatigue, and xerostomia). All of these exercises and additional information are within the normal standard of care and are simply facilitated outside of the clinical se tting by [CONTACT_941] “ HNC Virtual Coach ” program.  When two sequential exercise 
sessions in a row are not completed, the application will push a survey to the participant to ascertain the reason why the sessions were not completed. Available options will include: 1) Didn’t have time, 2) Pain, 3) Not feeling well/no energy, 4) Don’t know how to do them, 5) Don’t think they are necessary, 6) Issues with technology, and 7) Other.  Based on participant responses, the study team will have the option to push information to the participant to address cited issues. During the baseline visit, the patients will be instructed that this mode of communication is not intended to substitute the standard modes of communication with their provider, or obviate the need for scheduled follow-up visits.  The communication portal rather serves as a real -time feedback component on the patients “out of clinic” course of treatment.  
Arms/Groups if arms or groups have been specified for the protocol, all arms must be described and have at least one intervention (unless arm type is "No Intervention") and each intervention 
must be assigned to at least one arm.  
 
5.[ADDRESS_363679] app stores with the assistance of the research 
coordinator. 
 
 
6. ADVERSE EVENTS AND REPORTING PROCEDURES  
6.1 Potential Adverse Events 
No medical risks are expected to result from the use/implementation of the Vibrent
TM mobile 
application. The risk associated for all participants will not be greater than that of routine care for 
head and neck cancer patients receiving radiation therapy.  No direct risk is anticipated for completion of questionnaires or use of mobile appl ications as patients already have familiarity 
with these devices throughout their daily lives.  
 
 
Protocol version 9 /Version date 8 / June/2021
    24 6.2 Adverse Event Reporting  
Since this is a low -risk study with no anticipated adverse events (AE) related to the intervention, 
we will not be collecting any AEs or SAEs.  
 
 
Protocol version 9 /Version date 8 / June/2021
    25 7. STUDY CALENDAR  
Schedules shown in the Study Calendar below are provided as an example and should be 
modified as appropriate.  
    Pre-
Study1 Wk 
1 Wk 
2 Wk 
3 Wk 
 42 Wk 
5 Wk 
6 Wk 
73 Wk 
194 1 
Year5 
 
Optimize mobile application7  
X7  
  
  
  
  
  
  
  
  
 
Paper Logs12  X X X X X X X   
 
Informed consent   
X  
  
  
  
  
  
  
  
  
 
 
Demographic Survey 
(Appendix L)9  
X                  
 
Medical history10  
X  
  
  
  
  
  
  
  
  
 
 
Technology comfort scale  
(Appendix C)8  
X                   
 
MD Anderson Dysphagia 
Inventory  (Appendix E)   
X                
X  
X 
INFO 25 (Appendix K)  X        X  
 
Functional oral intake score 
(Appendix F)   
X        
X      
X  
X  
X 
 
Performance status scale H&N 
(Appendix G)   
X        
X      
X  
X  
X 
 
Weight  
X  
  
  
  
X  
  
  
X  
X  
X 
 
Maximal inter -incisor distance 
(mm)13  
X        
X      
X  
X  
X 
 
Modified barium swallow11  
X6  
  
  
  
  
  
  
  
X  
X 
Footnote: 
1. Procedures to be completed any time prior to start of radiation treatment.  If SOC procedures are 
completed prior to consent, they can be included, and do not need to be repeated.  
2. Procedures to be completed during Week 4 of radiation treatment (+/ - 2 days).  
3. Procedures to be completed during final week of radiation treatment (+/ - 2 days).  
 
Protocol version 9 /Version date 8 / June/2021
    26 4. Procedures to be completed 3 months  after end of radiation, ideally within  (+/- 2 weeks). 
However, if the procedures cannot be completed during that window (+/ -) 1 month is acceptable.  
5. Procedures to be completed 1 year after end of radiation (+/ - 1 month).  
6. Pre-study MBSS should occur prior to start of radiation treatment, but can also occur within 2 
days after start of radiation.  
7. For patients randomized in the app arm of the study.  
8. Part of the technology survey questions (the first 2 questions) are in the “pre -screening survey.” 
When the patient is completing the technology survey, the first 2 questions can be left blank if the 
participant has already answered them in the pre-screening survey (Appendix M) .   
9. In addition to Appendix L, the following demographic information will be collected from source 
documentation: date of birth, age at enrollment, miles from residence to treatment center  
10. Medical History: tumor site, TNM staging (8th edition), AJCC stage, HPV status, Primary 
treatment, Prescribed radiation dose (Gy), and Chemotherapy/Systemic Treatment  
11. Modified Barium Swallow Study metrics (Appendix I) completed along with Penetration Aspi[INVESTIGATOR_127353] (Appendix H) and DIGEST scores (Appendix J)  
12. For patients randomized to paper log arm of the study.  
13. Provide patients with standard scale to measure MIO during video visits (via mail or during in-person visit)  
 
Protocol version 9 /Version date 8 / June/[ADDRESS_363680] Clinical Trials Directory compliance   
Primary Outcome Measure Definition: Overall adherence to prescribed exercise protocol 
measured as percentage of prescribed exercises completed over a seven -week period. (i.e. if 
participants are asked to complete 6 sets of 10 reps of each exercise daily for 7 weeks, maximum potential would be 420 reps ). 
* Title: Exercise adherence * Time Frame: At the end of the 7 week treatment period * Safety Issue: No  
 
8.1  Primary Outcome Measure  
Adherence to prescribed exercise protocol  
  
(a) 8. 1.2 Measurement Definition  
 
Overall adherence to prescribed exercise protocol measured as percentage of prescribed 
exercises completed over a seven -week period. (i.e. if participants are asked to complete 6 sets of 
10 reps of each exercise daily for seven  weeks, maximum potential would be 420 reps ). 
  
(b) 8.1.3 Measurement Methods  
 
Participants will be asked to complete and log their swallow exercises using the either the 
Vibrent application or paper forms throughout the duration of radiation therapy and for 1 month after the completion of therapy. The Vibrent application will time stamp the date and time of data entry for secondary analysis to determine whether logging occurs on a daily basis or in batch. Paper logs will be collected by [CONTACT_298238] a central Redcap database.  
 
(c) 8.1.4 Measurement Time Points  
Adherence measures will be obtained at the conclusion of the 7- week treatment period.   
 
8.2a  Secondary Outcome measures (These measures, in combination, provide a 
comprehensive evaluation of swallowing physiology, its functional impact, and patient perception.)  
 
Patient reported:  
MD Anderson Dysphagia Inventory (MDADI)  
 
(d) 8.2a.2 Measurement Definition 
 
The MD Anderson Dysphagia Inventory (MDADI) was selected to capture and quantify the 
patient perception of swallowing dysfunction.  It is a 20- item patient reported survey that 
 
Protocol version 9 /Version date 8 / June/[ADDRESS_363681] of dysphagia on patients with HNC. Each item is scored on a 5 point scale 
with 1=lower function and 5=higher function. Possible scores range from 20- [ADDRESS_363682] deviation and 95% CI will be reported. 
 
(e) 8.2a.3 Measurement Methods 
 
MDADI: Each item is rated on a scale of 1 -5 with lower numbers indicating poorer function.  
Mean subscale scores are multiplied by 20 to provide a final score between 20 -100.  All 
participants will complete on paper forms.  
 
 
(f) 8.2a.4 Measurement Time Points  
 
Please see study schedule for the measurement time points.  
8.2b  Secondary Outcome measure  
 Functional Oral Intake Score (FOIS)  
 
(g) 8.2b.[ADDRESS_363683] deviation and 95% CI at each assessment (see study calendar).  
 
(h) 8.2b.3 Measurement Methods 
FOIS score will be given by [CONTACT_298239].  
 
(i) 8.2b.4 Measurement Time Points  
Please see study schedule for the measurement time points.  
 
8.2c  Secondary Outcome measure  
Performance Status Scale – Head and neck (PSS HN) 
 
(j) 8.2c.2 Measurement Definition 
The Performance Status Scale – Head and Neck (PSS-HN) was chosen to provide additional 
detail regarding diet and eating restrictions. The three items which will be administered include “eating in public”, “understandability of speech”, and “normalcy of die t”.  Each item ranges 
from [ADDRESS_363684] deviation and 95% CI at each assessment (see study calendar).  
 
(k) 8.2c.3 Measurement Methods 
PSS- HN will be completed by [CONTACT_298240].  
 
 
Protocol version 9 /Version date 8 / June/2021
    29 (l) 8.2c.4 Measurement Time Points  
Please see study schedule for the measurement time points.  
 
8.2d  Secondary Outcome measure  
Functional measures obtained during videofluoroscopic  swallowing studies (VFSS)  
Penetration Aspi[INVESTIGATOR_127353] (PAS) 
 
(m) 8.2d.[ADDRESS_363685] more severe laryngeal penetration/aspi[INVESTIGATOR_1516].  The mean group score for most severe PAS will be reported as well as standard deviation and 95% CI at each assessment (see study calendar). 
 
(n) 8.2d.3 Measurement Methods 
MBS ratings (PAS, MBS -Imp, DIGEST) will be rated by [CONTACT_298241].  
 
8.2d.4 Measurement Time Points  
Please see study schedule for the measurement time points.  
8.2e  Secondary Outcome measure  
Functional measures obtained during videofluoroscopic swallowing studies (VFSS)  
Individual item and composite scores of the Modified Barium Swallow Impairment Profile 
(MBS -ImP)  
 
(o) 8.2e.[ADDRESS_363686] deviation and 95% CI at each assessment (see study calendar).  
 
(p) 8.2e.3 Measurement Methods 
MBS ratings (PAS, MBS -Imp, DIGEST) will be rated by [CONTACT_298241].  
 
(q) 8.2e.4 Measurement Time Points  
Please see study schedule for the measurement time points.  
 
8.2f  Secondary Outcome measure  
Functional measures obtained during videofluoroscopic swallowing studies (VFSS)  
Dynamic Imaging Grade of Swallowing Toxicity (DIGEST) severity scores 
 
Protocol version 9 /Version date 8 / June/2021
    30  
(r) 8.2f.2 Measurement Definition 
The Dynamic Imaging Grade of Swallowing Toxicity was established to rate the safety and 
efficiency of the pharyngeal swallow during modified barium swallow studies using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE) framework.  This scale provides a safety impairment score, an efficiency impairment score, and an overall score.  Lower numbers on this scale are indicative of more normal function.  The mean group impairment scores will be reported as well as standard deviation and 95% CI at each assessment (see study calendar). 
 
(s) 8.2f.3 Measurement Methods 
MBS ratings (PAS, MBS -Imp, DIGEST) will be rated by [CONTACT_298241].  
 
(t) 8.2f.4 Measurement Time Points  
Please see study schedule for the measurement time points.  
 
 
8.2g  Secondary Outcome measure  
Maximal interincisal opening  
 
 
(u) 8.2g.2 Measurement Definition 
Maximal interincisor distance will be reported in mm as the space between the bottom of the 
upper incisor and the top of the lower incisor.  In patients missing dentition, 10mm will be 
deducted from this value for each missing incisor to represent the average incisal height.  
 
(v) 8.2g.[ADDRESS_363687] mm measuring tools will be used. 
 
(w) 8.2g.[ADDRESS_363688] Cancer Institute  Data and Safety Monitoring Committee (DSMC) will be the 
monitoring board for this study, please refer to the Data and Safety Monitoring Committee SOP  
for more information.  
 
11.1 Monitoring plan 
 
 
Protocol version 9 /Version date 8 / June/[ADDRESS_363689] Cancer Institute  Data and Safety Monitoring Committee (DSMC) will be the 
monitoring entity for this study. The DSMC will audit study- related activities approximately 
once per year to determine whether the study has been conducted in accordance with the 
protocol, local standard operating procedures, FDA regulations, and Good Clinical Practice (GCP).  This may include review of the following types of documents participating in the study: regulatory binders, case report forms, eligibility checklists, and source documents.  In addition, 
the DSMC will regularly review protocol deviations from all sites associated with the research to ensure the protection of human subjects. Results of the DSMC audit will be communicated to the IRB and the appropriate regulatory authorities at the time of continuing review, or in an expedited fashion, as needed.   
The Stanford Cancer Institute research team will conduct bi -annual audits of sub- site 
enrollment and regulatory compliance. This will include a review of one subject enrolled in that 
time period including case report forms, eligibility checklists, source d ocuments and regulatory 
binders. If no subjects have been enrolled in this time period, the audit will be skipped until the next cycle. The research team will also review protocol deviations and communicate findings with the DSMC and IRB as appropriate.  
 
 
11.2  Protocol Review and Amendments  
 
The protocol, the proposed informed consent and all forms of participant information related to 
the study (e.g. advertisements used to recruit participants) will be reviewed and approved by [CONTACT_298242] (SRC).  Any changes 
made to the protocol will be submitted as a modification and will be approved by [CONTACT_14226].  The Protocol Director will disseminate the protocol amendment to all participating investiga tors.  Investigators will be expected to obtain IRB approval within 90 days 
for all amendments.   
 
11.3  Data management  
The Protocol Director, or his/her designee, will prepare and maintain adequate and accurate 
participant case histories with observations and data pertinent to the study.  Study specific Case Report Forms (CRFs) will document treatment outcomes for data analysis.   Case report forms will be developed using the REDCap database system and will be maintained by [CONTACT_298243]. CRFs will be kept in a locked office, only accessible to the research team.  
 A chart with all of the relevant research patient information will be maintained for each patient at each institution, and the patient charts may be reviewed by [CONTACT_298244].  
Study data will be collected and managed using REDCap (Research Electronic Data Capture). 
REDCap is a secure, web application designed to support data capture for research studies. It provides user-friendly, web- based case report forms, real -time data entr y validation (e.g. for data 
types and range checks), audit trails and de-identified data export mechanism to common statistical packages (SPSS, SAS, Stata, R/S -Plus). The system was developed by a multi-
 
Protocol version 9 /Version date 8 / June/[ADDRESS_363690] University School of Medicine secure data center. The system is protected by [CONTACT_184289] (SSL) encryption  and a strong web based 
authentication system. Data collection is customized for each study or clinical trial based on a study-specific data dictionary defined by [CONTACT_298245]. Every personnel in the different sites is given access to only their specific site’s “Data Access Group” and can only see and enter information for their patients.  The Stanford research team  will manage  this access.  
 For patients randomized on the app arm of the study, some of their data will be captured via the VIbrent Health application. Vibrent Health has been deploying and managing solutions in highly regulated, highly secure, highly sensitive environments. Vibrent  Health  has supported and 
accredited solutions for the National Institute of Health (NIH), the US Army, commercial and military medical treatment facilities and hospi[INVESTIGATOR_600]. We understand the compliance requirements for these industries and the business requirements to protect the sensitive data that these businesses contain.  Vibrent  Health currently uses Cyber Secure Amazon AWS Cloud 
infrastructure to host the  Vibrent Platform.   Amazon AWS Cloud provides compliance with 
various Federal regulations that impa ct privacy and security requirements.  AWS Cloud is 
FedRAMP and FISMA certified and provides many other compliances and certifications such as HIPAA, SOC 1/2/3, PCI DSS Level 1, ISO [ZIP_CODE] and others.  AWS Data centers are housed in nondescript facilities and are not open to the public.  Vibrent Coaching Platform (VCP) App is based on a three -tier architecture consisting of web, 
application and data tiers.  The data tier consists of an Amazon Web Services RDS Aurora Multi zone deployment. The database contains all data interactions with the patients. The data tier is 
deployed upon AWS Aurora product which is Amazon’s custom MySQL offering. 
  
11.[ADDRESS_363691] be provided to the lead site when requested.  
 Participating Center’s PIs will be responsible for maintaining the clinical protocol and subjects’ study charts, assuring that consent is obtained and documented, and reporting the status of the trial in continuing renewals submitted to their IRB and trial monitoring group(s) as per their 
facility protocol.   Prior to a subsite’s start of enrollment, each subsite will be required to attend a teleconference where relevant Stanford research SOPs and documentation will be reviewed as mentioned in the Investiga tor Initiated Multisite Trial SOP.  
   
 
Protocol version 9 /Version date 8 / June/[ADDRESS_363692] every two months, although calls may occur more frequently if needed.   Teleconferences will be coordinated by [CONTACT_298246] a participating institution; PIs, Research Coordinators, Nurses, and Co- Investigators if needed will participate.  Any issues with patient 
compliance, database entry, or other items will also be disc ussed in these calls.  Calls may 
include review by [CONTACT_298247]; and the progress of the trial may also be discussed.  At times of study renewal or more frequently if needed, PIs may review safety  reports and clinical trial efficacy endpoints and confirm that the 
safety outcomes favor continuation of the study.  
 
 
10. STATISTICAL CONSIDERATIONS  
 
10.[ADDRESS_363693] with a primary aim of determining if a mobile application may 
enhance adherence to swallowing therapy in patients undergoing radiation for head and neck cancer thus improving swallowing outcomes.  Analysis of the primary endpoint (adherence) will be carried out using logistic regression, comparing arms A and B.  A secondary endpoint will be the average percent adherence per week.  Analysis of the secondary adherence endpoint will be carried out using a linear mixed effect model with weekly adherence as a dependent variable, a patient- specific random intercept, treatment arm as the primary predictor, and week as a fixed 
(categorical) effect. We will also explore the impact of the mobile app on a variety of swallowing outcomes including diet level, patient perception, and physiological measures.  Analysis of these endpoints will be carried out using logistic regression comparing arms A and B. 
 
(x) Randomization  
Randomization will be carried out using pre- printed lists with block size of 4 . 
 
10.4 Primary Analysis  
Analysis of the primary endpoint (adherence) will be carried out using logistic regression, 
comparing arms A and B.  Analysis of the secondary adherence endpoint will be carried out using a linear mixed effect model with weekly adherence as a dependent variable, a patient -
specific random intercept, treatment arm as the primary predictor, and week as a fixed (categorical) effect.  
 
(y) Analysis Population 
Analysis will include all participants.  
 
 
Protocol version 9 /Version date 8 / June/2021
    34 (z) Analysis Plan  
As above 
 
12.[ADDRESS_363694] of the mobile app on a variety of swallowing outcomes 
including diet level, patient perception, and physiological measures.  Analysis of these endpoints will be carried out using logistic regression comparing arms A and B.  
 
(aa) 12.5.1  Analysis Population 
Analysis will include all participants . 
 
(bb) 12.5.2  Analysis Plan 
As above 
 
12.6  Sample Size  
(cc) 12.6.[ADDRESS_363695] 3 years. 
 
(dd) 12.6.2 Sample size justification  
 
88 patients will be enrolled in each arm.  This number will provide 80% power to detect a 15 
percentage point difference between groups. This sample size includes the addition of 20% to account for anticipated drop out.  
 
(ee) 12.6.[ADDRESS_363696] size justification  
This calculation is made assuming 33% adherence in arm B and a standard deviation of 32 based on prior studies. 
 
 
Protocol version 9 /Version date 8 / June/2021
    35 13. REFERENCES  
Achim V, Bolognone RK, Palmer AD, et al.  Long- term functional and quality of 
life outcomes after transoral robotic surgery in patients with oropharyngeal 
cancer.  JAMA Otolaryngol Head Neck Surg 2017; Oct 26.  
 Altman K.W., Yu G.P., & Schaefer S.D. (2010).  Consequence of dysphagia in the hospi[INVESTIGATOR_105458]: impact on prognosis and hospi[INVESTIGATOR_256944].  Arch Otolaryngol Head Neck Surg; 136(8): 784- 9. 
 Anderson M.  (2015). Technology device ownership: 2015: Pew research center. http://www.pewinternet.org/2015/10/29/technology -device- ownership- 2015/   
Accessed 8/10/17.  
 Barbieri J.S., Nelson C.A., James W.D., et al.  (2014).  The reliability of teledermatology to triage inpatient dermatology consultations.  JAMA Dermatol; 150: 419- 24. 
 Carnaby -Mann G., Crary M.A., Schmalfus I., & Amdur R.  “Pharyngocise”: 
randomized control trial of preventative exercises to maintain muscle structure and swallowing function during head and neck chemoradiotherapy. (2012).  Int J Rad Onc Bio Phys, 83: 210- 9. 
 Carroll W.R., Locher  J.L., Canon C.L., Bohannon I.A., McColloch N.L., & 
Magnuson J.S. Pretreatment swallowing exercises improve swallow function after chemoradiation. (2008).  Laryngoscope,118, 39- 43. 
 Carter M.C., Burley V.J., Nykjaer C., & Cade J.E. Adherence to a smartphone application for weight loss compared to website and paper diary: Pi[INVESTIGATOR_2269]. (2013). J Med Internet Res , 15, e- 32. 
 
 
Protocol version 9 /Version date 8 / June/2021
    36 Chaturvedi AK, Engels EA, Anderson WF, et al.  (2008). Incidence trends for 
human papi[INVESTIGATOR_27509] -related and - unrelated oral squamous cell carcinomas in 
the [LOCATION_002].  J Clin Oncol , 26, 612- 9. 
 Chaturvedi A.K., Engels E.A., Pfeiffer R.M., Hernandez B.Y., Xiao W., & … (2011). Human Papi[INVESTIGATOR_298221].  J Clin Oncol, 29(32): 4294- 301. 
 Chen A.Y., Frankowski R., Bishop- Leone J., Hebert T., Leyk S., Lewin J., & 
Goepfert H.  (2001). The development and validation of a dysphagia- specific 
quality of life questionnaire for head and neck cancer.  JAMA Otolaryngol Head Neck Surg; 127(7): 870- 6. 
 
Cnossen I.C., van Uden- Kraan C.F., Witte B.I., Aalders Y.J., de Goede C.J., de 
Bree R., & … (2017) Prophylactic exercises among head and neck cancer patients during and after swallowing sparing intensity modulated radiation: adherence and exercise performance levels of a 12- week guided home based 
program. Eur Arch Otorhinolaryngol; 274(2): 1129- 38. 
 Crary M.A., Mann G.D., & Groher M.E. (2005).  Initial psychometric assessment of a functional oral intake scale for dysphagia in stroke patients.  Arch Phys Med Rehabil; 86(8): 1516- 20. 
 
Daugaard R, Kjaer T, Johanset  C, et al.  (2017).  Association between late 
effects assessed by [CONTACT_298248].  Acta Oncol , Jan 12: 1- 6. 
 Ekberg O.  Dysphagia: Diagnosis and Treatment.  Springer, 2012.  
 
 
Protocol version 9 /Version date 8 / June/[ADDRESS_363697] CR, et al.  (2002). Objective assessment of 
swallowing dysfunction and aspi[INVESTIGATOR_298222]. Int J Radiat Oncol Biol Phys ,  53, 23- 8. 
 
Fakhry C., Westra W.H., Li S., et al. (2008). Improved survival of patients with human papi[INVESTIGATOR_28597] –positive head and neck squamous cell carcinoma in a 
prospective clinical trial. J Natl Cancer Inst , 100, 261- 269. 
 Forkan R, Pumper B, Smyth N, Wirkkala H, Ciol MA, Shumway -Cook A.  (2006). 
Exercise adherence following physical therapy intervention in older adults with impaired balance.  Phys Ther ; 86: 401- 10. 
 Fujiu M. & Logemann J.A. Effect of a tongue- holding maneuver on posterior 
pharyngeal wall movement during deglutition.  (1996) Am J Speech Lang Pathol; 5:23- 30. 
 Gane EM, McPhail SM, Hatton AL, Panizza BJ, O’Leary SP.  Predictors of health- related quality of life in patients treated with neck dissection for head and 
neck cancer.  Eur Arch Otorhinolaryngol 2017; 274(12): 4183- 93. 
 Gillison M.L., D'Souza G., Westra W., et al. (2008). Distinct risk factor profiles for human papi[INVESTIGATOR_61382] 16- positive and human papi[INVESTIGATOR_61382] 16-
negative head and neck cancers. J Natl Cancer Inst , 100, 407- 420. 
 
Guarino H, Acosta M, Marsch LA, Xie H, Aponte- Melendez Y.  (2016).  A mixed-
methods evaluation of the feasibility, acceptability, and preliminary efficacy of a 
mobile intervention for methadone maintenance clients.  Psychol Addict Behav , 
30(1): 1- 11. 
 
Hardage J, Peel C, Morris D, et al. (2007). Adherence to exercise scale for older 
patients (AESOP): a measure for predicting exercise adherence in older adults 
 
Protocol version 9 /Version date 8 / June/2021
    38 after discharge from home health physical therapy.  J Geriatr Phys Ther ; 30: 69-
78. 
 
Hoffman M.R., Mielens J.D., Ciucci M.R., Jones C.A., Jiang J.J., & McCulloch 
T.M.  (2012).  High- resolution manometry of pharyngeal swallow pressure events 
associated with effortful swallow and the Mendelsohn Maneuver.  Dysphagia ; 
27(3): 418- 26. 
 
Hui CY, Walton R, McKinstry B et al.  (2016).  The use of mobile applications to 
support self -management for people with asthma: a systematic review of 
controlled studies to identify features associated with clinical effectiveness and 
adherence.  J Am Med Inform Assoc , Oct 2.  
 
Hutcheson K.A., Barrow M.P., Barringer D.A., Knott J.K., Lin H.Y., Weber R.S., & … (2017).  Dynamic Imaging Grade of Swallowing Toxicity (DIGEST): scale development and validation.  Cancer; 123(1): 62- 70. 
 Hutcheson KA, Bhayani MK, Beadle BM, et al.  (2013). Eat and exercise during 
radiotherapy or chemoradiotherapy for pharyngeal cancers: use it or lose it.  
JAMA Otolaryngol Head Neck Surg, 139 (111): 1127- 34. 
 Hutcheson KA, Lewin JS, Barringer DA, et al.  (2012). Late dysphagia after 
radiotherapy -based treatment of head and neck cancer.  Cancer , 118, 5793- 9. 
 
Jemal A., Simard E.P., Dorell C., et al. (2013). Annual report to the nation on the 
status of cancer 1975- 2009, featuring the burden and trends in human 
papi[INVESTIGATOR_28597] (HPV) -associated cancers and HPV vaccination coverage levels.  
J Natl Cancer Inst, 105: 175- 201. 
 Jones E, Speyer R, Kertscher B, et al.  Health- Related quality of life and 
oropharyngeal dysphagia: A systematic review.  Dysphagia 2017; Sept 02.  
 
Protocol version 9 /Version date 8 / June/2021
    39  
King SN, Dunlap NE, Tennant PA, Pi[INVESTIGATOR_7929] T.  (2016).  Pathophysiology of radiation-induced dysphagia in head and neck cancer.  Dysphagia, 31, 339- 51. 
 Kotz T., Federman A.D., Kao J., Milman L, Packer S., Lopez -Prieto C., … & 
Genden E.M.  Prophylactic swallowing exercises in patients with head and neck cancer undergoing chemoradiation: a randomized trial. (2012). Arch Otolaryngol Head Neck Surg, 138, 376- 82. 
 Langendijk J.A., Doornaert P., Verdonck -de Leeuw I., Leemans C.R., Aaronson 
N.K., & Slotman B.J. (2008). Impact of late treatment- related toxicity on quality of 
life among patients with head and neck cancer treated with radiotherapy.  J Clin Oncol, 26: 3770- 6. 
 Lazarus C., Logemann J.A., Song C.W., Rademaker A.W., & Kahrilas P.J. (2002).  Effects of voluntary maneuvers on tongue base function for swallowing.  Folia Phoniatrica Et Logopaedica: Official Organ of the International Association of Logopedics and Phoni atrics (IALP); 54(4): [ADDRESS_363698] M.A., Ritter- Sterr C., Lansky S.B. (1990). A performance status scale for 
head and neck cancer patients.  Cancer; 66: 564- 9. 
 
Logemann J.A., Pauloski B.R., Rademaker  A.W., & … (1997). Speech and 
swallowing rehabilitation for head and neck cancer patients.  Oncology; 11: 651-9. 
 Martin -Harris B., Brodsky M.B., Michel Y., Castell D.O., Schleicher M., Sandidge 
J., & … (2008). MBS measurement tool for swallow impairment – MBSImp: 
establishing a standard.  Dysphagia; 23(4): 392- 405. 
 
 
Protocol version 9 /Version date 8 / June/2021
    40 McLean S, Holden MA, Potia T, et al. (2017). Quality and acceptablility of 
measures of exercise adherence in musculokeletal settings: a systematic review. Rheumatology ; 56:: 426- 38. 
 Mortensen H.R., Jensen K., Aksglaede K., Lambertsen K., Eriksen E., & Grau C. (2015). Prophylactic swallowing exercises in head and neck cancer radiotherapy.  
Dysphagia; 30(3): 304 -14. 
 Nelson C.A., Wanat K.A., Roth R.R. et al. (2015). Teledermatology as pedagogy: diagnostic and management concordance between resident and attending dermatologists.  J Am Acad Dermatol; 72: 555- 7. 
 Nguyen N.P., Frank C., Moltz C.C., Vos P., Smith H.J., Karlsson U., & … (2005). Impact of dysphagia on quality of life after treatment of head and neck cancer.  Int J Radiat Oncol Biol Phys, 61: 772- 8. 
 Nguyen N.P., Franc C., Mottz C.C., Vos P., Smith H.J., Bhamidipati  P.V., & … 
(2006). Aspi[INVESTIGATOR_298223]: an 
underreported occurrence.  Radiother Oncol, 80: 302- 6. 
 
Nguyen N.P., Sallah S., Karlsson U., & Antoine J.E. (2002). Combined chemotherapy and radiation therapy for head and neck malignancies: quality of life issues.  Cancer, 94: 1131- 41. 
 
Ringash J.  (2015).  Survivorship and quality of life in head and neck cancer.  J 
Clin Oncol , 33(29): 3322- 7. 
 Rosenbek J.C., Robbins J.A., Roecker E.B., Coyle J.I., & Wood J.L. (1996).  A penetration -aspi[INVESTIGATOR_127390].  Dysphagia; 11: 93- 98. 
 
 
Protocol version 9 /Version date 8 / June/2021
    41 Rosenthal DL, Mendoza TR, Fuller CD, et al.  Patterns of symptom burden 
during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: a prospective analysis using the University of [LOCATION_007] MD Anderson Cancer Center Symptom Inventory – Head and Neck Module.  Cancer 2014; 120(13): 
1975- 84. 
 Sabate E.  Adherence to long- term therapi[INVESTIGATOR_014]: Evidence for Action.  Geneva, 
Switzerland: World Health Organization; 2003.  
 Serra Prat M., Palomera M., Gomez C., Sar- Shalom D., Saiz A., Montoya J.G., & 
… (2012) Oropharyngeal dysphagia as a risk factor for malnutrition and lower respi[INVESTIGATOR_298224]: a population-based prospective study.  Age and aging; 41(3): 376- 81. 
 Sharma A, Mendez E, Yueh B, et al.  (2012). Human papi[INVESTIGATOR_28597] -positive oral 
cavity and oropharyngeal cancer patients do not have better quality -of-life 
trajectories.  Otolaryngol Head Neck Surg, 146, 739- 45. 
 
Shinn EH, Basen- Engquist K, Baum G, et al.  (2013). Adherence to preventative 
exercisesand self -reported swallowing outcomes in post -radiation head and neck 
cancer patients.  Head Neck , 35, 1707- 12. 
 
Silveira MH, Dedivitis RA, Queija DS, Nascimento PC.  (2015).  Quality of life in 
swallowing disorders after nonsurgical treatment for head and neck cancer.  Int 
Arch Otorhinolaryngol , 19(1): 46- 54. 
 
Starmer HM, Abrams R, Webster K, et al.  (2017). Feasibility of a mobile 
application to enhance swallowing therapy for patients undergoing radiation-
based treatment for head and neck cancer.  Dysphagia, Sept 30 2017.  
 
Starmer H, Sanguineti G, Marur S, Gourin CG. (2011) Multidisciplinary head and 
 
Protocol version 9 /Version date 8 / June/2021
    42 neck cancer clinic and adherence with speech pathology. Laryngoscope, 121, 
2131- 5. 
 
Starmer HM, Tippett D, Webster K, et al.  (2014). Swallowing outcomes in patients with oropharyngeal cancer undergoing organ- preservation treatment.  
Head Neck , 36, 1392- 7. 
 
Starmer HM, Yang W, Raval  R et al.  (2014). Effect of gabapentin on swallowing 
during and after chemoradiation for oropharyngeal squamous cell cancer.  
Dysphagia, 29, 396- 402. 
 Turner T. & Hingle M.  (2017). Evaluation of a mindfulness -based mobile app 
aimed at promoting awareness of weight -related behaviors in adolescents: A pi[INVESTIGATOR_11480].  JMIR Res Protoc; 6: e67.  
 Turner -McGrievy G.M., Beets M.W., Moore J.B., Kaczynski A.T., Barr- Anderson 
D.J., & Tate D.F. (2013). Comparison of traditional versus mobile app self -
monitoring of physical activity and dietary intake among overweight adults 
participating in an mHealth weight loss program.  J Am Med Informatics Assn. 
20: 513- 18. 
 Wall L.R., Ward E.C., Cartmill B., Hill A.J., & Porceddu S.V. (2017). Adherence to a prophylactic swallowing therapy program during (chemo) radiotherapy: Impact of service delivery model and patient factors.  Dysphagia; 32(2): 279- 92. 
 
Yang W, McNutt T, Dudley S, et al.  (2016).  Predictive factors for prophylactic 
percutaneous endoscopic gastrostomy (PEG) tube placement and use in head 
and neck patients following intensity -modulated radiation therapy (IMRT): 
treatment concordance, discrepancies, and the role of gabapentin.  Dysphagia . 
31, 206- 13. 
 
Protocol version 9 /Version date 8 / June/2021
    43 APPENDICES  
APPENDIX A: Participant Eligibility Checklist  
 
Protocol Title:       Investigation of Two Swallowing Therapy Models 
during Radiation Therapy for Head and Neck 
Cancer   
 
 
Protocol Number:  IRB-[ZIP_CODE]  
Principal 
Investigator:  [INVESTIGATOR_298225]. Subject Information:  
 
Subject Name/ID:   
Gender:     Male      Female  
III. Study Information:  
SRC Approved  IRB Approved  Contract signed  
IV. Inclusion/Exclusion Criteria  
 
Inclusion Criteria  
(From IRB approved protocol)  Yes No Supporting Documentation*  
1. Age ≥ [ADDRESS_363699] capable of 
providing informed consent          
4. Patient with newly diagnosed non-metastatic head and neck 
cancer such as cancer of the 
oral cavity, oropharynx, nasopharynx, hypopharynx, and larynx that require bilateral neck radiation.  Individuals with unknown primary head and neck cancer with nodal disease necessitating bilateral radiation 
will also be included.          
 
Protocol version 9 /Version date 8 / June/2021
    44 5. No prior history of surgery  and/ 
or radiation of the head and 
neck for another malignancy          
6. Study subject with a previously 
untreated head and neck cancer diagnosis requiring a definitive course of radiotherapy requiring a 
prescribed dose of 60Gy or 
greater.          
Exclusion Criteria  
(From IRB approved protocol)  Yes         No  
1. Lack of smartphone, tablet, or 
Internet connection.          
2. Patients with recurrent 
disease.          
3. Individuals with 
contraindications to radiation 
therapy.          
*All subject files must include supporting documentation to confirm subject 
eligibility.  The method of confirmation can include, but is not limited to, laboratory test results, radiology test results, subject self -report, and medical 
record review.   
IV.  Statement of Eligibility  
By [CONTACT_114052] I verify that this subject is [
 eligible  /  ineligible ] for 
participation in the study. This study is approved by [CONTACT_298249], the Stanford IRB, and has finalized  financial and 
contractual agreements as required by [CONTACT_114054]’s Research 
Management Group.   
 
Treating Physician Signature:  [CONTACT_1782]:  
Printed Name:  
 
[CONTACT_298253] : Date:  
Printed Name:  
 
[CONTACT_115211]:  Date:  
Printed Name:  
[CONTACT_298254] 9 /Version date 8 / June/2021 45Appendix C: Patient Comfort with Technology
1.Do you own either an Android or Apple- iOS based smartphone or tablet?
Yes                                                No
2.Do you have access to an internet connection or a sufficient monthly data 
plan (~200MB/month) or greater?
Yes                                                No
3.Please mark on the line to indicate your comfort using technology.
Very uncomfortable     Very comfortable
4.Please mark on the line to indicate your comfort using your smartphone.
Very uncomfortable                    Very comfortable
5.Please mark on the line to indicate your comfort using your tablet.
Very uncomfortable Very comfortable

 
Protocol version 9 /Version date 8 / June/2021
    46 Appendix D: Paper logging form  
 
Exercise logging form: Please indicate the number of sets of exercises prescribed you 
completed and denote your level of pain after completing the sets of exercises with 1 being no 
pain, and 10 extreme:  
  
 Day 1  Day 2  Day 3  Day 4  Day 5  Day 6  Day 7  
Date         
AM        
PM        
Pain 
Level (1-10)        
 
 
 
  
Participant Name: ______________________________________    
 
Protocol version 9 /Version date 8 / June/2021
    47 Appendix E : MD Anderson Dysphagia Inventory  
 
 
     
  

 
Protocol version 9 /Version date 8 / June/2021
    48  
 
  
 
 

 
Protocol version 9 /Version date 8 / June/2021
    49 Appendix F : Functional Oral Intake Scale (FOIS) 
 
Level 1:  Nothing by [CONTACT_298250] 2: Tube dependent with minimal attempts of food or liquid  
Level 3: Tube dependent with consistent oral intake of food or liquid  
Level 4:  Total oral diet of a single consistency  
Level 5:  Total oral diet of multiple consistencies but requiring special preparation or compensations  
Level 6: Total oral diet of multiple consistencies without special preparation but with specific food limitations  
Level 7: Total oral intake without restrictions  
  
 
Protocol version 9 /Version date 8 / June/2021
    50 Appendix G : Performance Status Scale – Head and Neck  
 
Eating in Public 
 _____ No restriction of place, food, or companion (eats out at any opportunity) (100)  
 _____ No restriction of place but restricts diet when in public(eats anywhere but may limit intake   
to less “messy” foods, e.g. liquids) (75)  
_____ Eats only in presence of selected persons in selected places (50) 
_____ Eats only at home in presence of selected persons (25)  
_____ Always eats alone (0)  
 
Understandability of speech  
_____ Always understandable (100)  
_____ Understandable most of the time; occasional repetition necessary (75)  
_____ Usually understandable; face to face contact [CONTACT_298251] (50)  
_____ Difficult to understand (25)  
_____ Never understandable; may use written communication (0)  
 
Normalcy of diet  _____ Full diet (no restrictions) (100)  
_____ Peanuts (90)  
_____ All meat (80)  
_____ Carrots, celery (70)  
_____ Dry bread and crackers (60)  
_____ Soft, chewable foods (e.g. macaroni, canned/soft fruits, cooked vegetables, fish, 
hamburger, small pi[INVESTIGATOR_298226]) (50)  
_____ Soft foods requiring no chewing (e.g. mashed potatoes, applesauce, pudding) (40)  
_____ Pureed foods (in blender) (30)  
_____ Warm liquids (20)  
_____ Cold liquids (10)  
_____ Nonoral feeding (tubefed) (0)  
  
 
Protocol version 9 /Version date 8 / June/2021
    51 Appendix H: Penetration Aspi[INVESTIGATOR_298227]  
[ADDRESS_363700] 
 
  
 
Protocol version 9 /Version date 8 / June/2021
    52  
Appendix I : Modified Barium Swallow Impairment Profile (MBS -Imp)  
 
  

 
Protocol version 9 /Version date 8 / June/2021
    53  
Appendix J : Dynamic Imaging Grade of  Swallowing Toxicity 
 
 
 

 
Protocol version 9 /Version date 8 / June/2021
    54 Appendix K: INFO 25 Survey  
 

 
Protocol version 9 /Version date 8 / June/2021
    55  

 
Protocol version 9 /Version date 8 / June/2021
    56 Appendix L: Demographic Survey  
 
 
 
 
 
 
        
 
 
  
 
 
 
 
 
 
 
     
 
   
 
 
       

 
Protocol version 9 /Version date 8 / June/2021
    57 Appendix M: Pre -screening Questionnaire  
 
1. Do you own either an Android or Apple- iOS based smartphone or tablet?  
 
 
Yes                                                No 
 
  
2. Do you have access to an internet connection or a sufficient monthly data plan (~200MB/month) or greater? 
  
Yes                                                No 
 